Alzecure Pharma
Headquarters: Stockholm, Sweden
Founded: 2015
Status: Public company (Nasdaq Stockholm: ALZCUR)
CEO: Eva-Lotta Allen
Market Cap: ~$100M USD (2026)
Website: [alzecure.com](https://www.alzecure.com)
Overview
Mermaid diagram (expand to render)
AlzeCure Pharma AB is a Swedish biotechnology company focused on developing novel therapeutics for Alzheimer's disease and other neurodegenerative disorders. The company was founded in 2015 as a spinout from the Karolinska Institutet in Stockholm, Sweden, with the mission of translating academic research on neurotrophic mechanisms into clinical-stage treatments for cognitive disorders["@alzecure"].
The company's approach focuses on targeting neurotransmitter systems, particularly the cholinergic system, which is critically involved in memory and cognitive function. Unlike the many companies pursuing amyloid-targeting approaches, AlzeCure takes a distinctly different strategy by enhancing endogenous neuroprotective mechanisms through positive modulation of neurotrophin receptors. This approach aims to protect existing neurons, enhance synaptic function, and preserve cognitive capacity in patients with Alzheimer's disease["@alzforum"].
Scientific Foundation
The Cholinergic Hypothesis
AlzeCure's therapeutic approach is grounded in the cholinergic hypothesis of Alzheimer's disease, which posits that loss of cholinergic neurons in the basal forebrain significantly contributes to cognitive decline[@cholinergic_hypothesis]:
Historical Context: The cholinergic hypothesis emerged from observations that:
- AD patients show severe loss of cholinergic neurons in the nucleus basalis of Meynert
- Cholinergic markers (acetylcholine, choline acetyltransferase) are reduced in AD brains
- Anticholinergic drugs cause memory impairment in healthy subjects
- Cholinesterase inhibitors provide modest but real cognitive benefit
Limitations of Current Approaches: While cholinesterase inhibitors (donepezil, rivastigmine, galantamine) are approved for AD and provide symptomatic benefit, they:
- Do not address the underlying neurodegeneration
- Have limited efficacy and eventually lose effectiveness
- Only replace lost acetylcholine without protecting neurons
AlzeCure's Innovation: Rather than simply increasing acetylcholine levels, AlzeCure aims to protect and enhance the cholinergic system itself through neurotrophin receptor modulation[@cholinergic_hypothesis][@trka_ngf].
Neurotrophin Receptor Biology
The company's lead programs target tropomyosin receptor kinase A (TrkA) and its ligand nerve growth factor (NGF)[@trka_ngf][@neurotrophin_signaling]:
TrkA Receptor:
- High-affinity receptor for NGF
- Expressed primarily on cholinergic neurons in the basal forebrain
- Activation promotes neuronal survival, differentiation, and synaptic plasticity
- NGF/TrkA signaling declines with age and in AD
Signaling Pathways:
- PI3K/Akt pathway: Pro-survival signaling, anti-apoptotic
- MAPK/ERK pathway: Neuronal differentiation, synaptic plasticity
- PLCγ pathway: Calcium signaling, neurotransmitter release
Therapeutic Rationale: By positive allosteric modulation of TrkA, AlzeCure's compounds can:
- Enhance cholinergic neuron survival
- Promote synaptic formation and function
- Protect against amyloid and other toxic insults
- Support memory and cognitive processes
Pipeline Overview
AlzeCure maintains a focused pipeline of programs targeting different aspects of AD:
| Program | Mechanism | Indication | Phase | Status |
|---------|-----------|------------|-------|--------|
| ACD856 | TrkA positive allosteric modulator | Alzheimer's Disease | Phase 1 | Active |
| ACD680 | 5-HT6 receptor antagonist | Alzheimer's Disease | Preclinical | Research |
| ACD747 | NGF modulator | Alzheimer's Disease | Discovery | Research |
Lead Program: ACD856
Mechanism of Action
ACD856 is a first-in-class small molecule that acts as a positive allosteric modulator of the TrkA receptor and its ligand NGF[@trka_ngf][@trk_agonists]:
TrkA Modulation:
- Binds to an allosteric site on TrkA
- Enhances NGF binding affinity and signaling efficacy
- Does not directly activate TrkA (requires NGF presence)
- Provides physiological activation rather than artificial stimulation
NGF Pathway Activation:
By potentiating NGF signaling, ACD856 promotes:
- Cholinergic neuron survival and function
- Synaptic plasticity and memory formation
- Neuroprotection against various insults
- Enhanced hippocampal cognitive function
Distinct from Amyloid Approaches:
Unlike anti-amyloid antibodies, ACD856:
- Does not target Aβ or tau pathology directly
- Works on downstream effects of neurodegeneration
- May benefit patients regardless of amyloid burden
- Has a different mechanism for cognitive enhancement
Clinical Development
ACD856 entered Phase 1 clinical trials in 2024 with a first-in-human study evaluating safety, tolerability, and pharmacokinetics in healthy volunteers[@acd856_p1]:
Phase 1 Program Design:
| Component | Description | Status |
|-----------|-------------|--------|
| Single ascending dose (SAD) | Dose-escalation in healthy volunteers | Completed |
| Multiple ascending dose (MAD) | Repeat dosing to assess steady-state PK | Completed |
| Food effect study | Impact of food on absorption | Completed |
| Cognitive endpoints | Exploratory cognitive assessments | Ongoing |
Study Design Highlights:
- Randomized, double-blind, placebo-controlled
- Single and multiple dose escalation
- PK/PD assessments including neurotrophin levels
- Safety monitoring with cognitive battery
Rationale for Target[@synaptic_function][@neuronal_survival]:
The cholinergic hypothesis of Alzheimer's disease posits that loss of cholinergic neurons contributes significantly to cognitive decline. By enhancing TrkA/NGF signaling, ACD856 aims to:
Protect cholinergic neurons from degeneration through enhanced pro-survival signaling
Enhance synaptic plasticity and memory formation through strengthened neuronal connections
Provide symptomatic benefit through a non-amyloid mechanism
Potentially modify disease progression by preserving functional neuronsPreclinical Evidence
ACD856 has demonstrated significant preclinical activity:
In Vitro Studies:
- TrkA activation in cell-based assays
- Neuroprotection against toxic insults
- Enhanced synaptic markers in neuronal cultures
In Vivo Studies:
- Improved performance in memory tasks (Morris water maze, novel object recognition)
- Increased hippocampal synaptic density
- Enhanced cholinergic neuron survival in AD models
- Good brain penetration and exposure
Translational Biomarkers:
- Target engagement biomarkers in development
- CSF sampling for pharmacodynamic assessments
- Neuroimaging endpoints under consideration
AlzeCure leverages a proprietary platform developed from academic research at Karolinska Institutet[@karolinska_research][@swedish_biotech]:
Key Capabilities
| Platform | Application | Status |
|----------|-------------|--------|
| Neurodegeneration models | In vitro and in vivo disease modeling | Established |
| Cognitive testing | Rodent behavioral assays | Validated |
| Pharmacokinetics | PK/PD optimization | Active |
| Medicinal chemistry | Lead optimization | Ongoing |
Discovery Approach
The company's drug discovery process integrates:
Target identification from academic research
High-throughput screening for lead compounds
Structure-activity relationship optimization
In vitro pharmacology characterization
In vivo efficacy testing in disease models
Clinical candidate selection and advancementCollaborations
AlzeCure maintains academic collaborations:
- Karolinska Institutet: Ongoing research partnership
- Swedish universities: Basic neuroscience research
- European Union: Research funding collaborations
- Swedish research councils: Grant support
The company has also received funding from:
- European Innovation Council
- Vinnova (Swedish innovation agency)
- Swedish Research Council
5-HT6 Receptor Antagonist Program: ACD680
Background
The 5-HT6 receptor is a promising target for Alzheimer's disease cognitive enhancement[@5ht6_antagonists]:
5-HT6 Receptor Biology:
- G-protein coupled receptor expressed in brain regions important for cognition
- Modulates GABAergic, glutamatergic, and cholinergic neurotransmission
- Antagonism enhances cognitive function in preclinical models
- Several 5-HT6 antagonists have been in clinical development
Rationale for 5-HT6 Antagonism:
- 5-HT6 antagonists enhance acetylcholine release
- Improve glutamatergic signaling important for learning
- Reduce GABAergic inhibition in hippocampal circuits
- Have shown cognitive benefits in clinical trials
Development Status
ACD680 is in preclinical development with the goal of advancing to IND-enabling studies:
- Lead optimization completed
- In vivo efficacy demonstrated
- Safety assessment initiated
Neurotrophic Modulation: ACD747
Approach
ACD747 represents a different approach to neurotrophin modulation:
- Modulates NGF directly or its interactions with TrkA
- Novel mechanism distinct from TrkA PAMs
- Currently in discovery phase
Potential Advantages
- May provide different pharmacodynamic effects
- Could be combined with ACD856 in future
- Addresses additional aspects of neurotrophin biology
Financial Status
AlzeCure is a publicly traded company listed on Nasdaq Stockholm[@alzecure]:
| Metric | Value |
|--------|-------|
| Stock exchange | Nasdaq Stockholm |
| Ticker | ALZCUR |
| Market cap | ~$100M USD |
| Cash position | Sufficient for operations through 2026 |
Funding History:
- IPO on Nasdaq Stockholm (2019)
- Multiple equity offerings
- Grant funding from EU and Swedish sources
- Ongoing business development efforts
Competitive Landscape
AlzeCure operates in the Alzheimer's disease therapeutic space:
Non-Amyloid Approaches
| Company | Drug/Approach | Mechanism | Status |
|---------|--------------|-----------|--------|
| AlzeCure | ACD856 | TrkA PAM | Phase 1 |
| Neurocentria | NC-601 (Magnesium L-threonate) | NMDA modulation | Phase 2 |
| Cognition Therapeutics | CT1812 | Sigma-2 receptor antagonist | Phase 2 |
| AstraZeneca | AZD0530 | Src inhibition | Phase 2 |
| Cerevel | CVL-231 | M1 PAM | Phase 2 |
Cholinergic Approach Comparison
| Company | Drug | Target | Status |
|---------|------|--------|--------|
| AlzeCure | ACD856 | TrkA | Phase 1 |
| Axovant | intepirdine | 5-HT6 antagonist | Failed Phase 3 |
| Heptares | HTL0018318 | M1 PAM | Phase 2 |
| AstraZeneca | AZD2327 | M1 PAM | Phase 2 |
AlzeCure's differentiation comes from:
- Direct enhancement of neurotrophin signaling
- Non-amyloid mechanism
- Focus on neuroprotection rather than symptomatic relief
- Strong academic foundation from Karolinska
Market Opportunity
The Alzheimer's disease market represents significant opportunity:
Market Size
- Global AD therapeutics: $10B+ annually
- Projected 2030: $20B+ with disease-modifying therapies
- Unmet need: Significant for non-amyloid approaches
Competitive Advantages
AlzeCure's approach addresses:
Limited amyloid efficacy: Many anti-amyloid approaches show modest benefit
Symptomatic gap: No disease-modifying options currently approved
Patient heterogeneity: Mechanism may benefit diverse patient populations
Combination potential: Could be combined with other approachesRegulatory Pathways
- Clear regulatory pathway with established endpoints
- Potential for accelerated approval based on biomarker evidence
- Flexible development options (monotherapy or combination)
Challenges and Risks
Development Risks
Clinical success uncertainty: Phase 1 results will determine path forward
Competition: Many companies in AD space, limited success to date
Regulatory requirements: May require large Phase 3 programs
Funding needs: Significant capital required for late-stage developmentBusiness Risks
Partnership dependence: May need pharma partnership for commercialization
Market access: Pricing and reimbursement challenges in AD
Competition from biosimilars: Future generic competitionFuture Directions
Near-term (2026-2027)
- Complete Phase 1 clinical trials
- Evaluate Phase 2 readiness
- Assess partnership opportunities
- Advance ACD680 toward IND
Medium-term (2027-2030)
- Potential Phase 2 initiation for ACD856
- Regulatory interactions for pivotal trial design
- Business development for commercialization partnership
- Continued pipeline advancement
Strategic Priorities
- Establish clinical proof-of-concept for ACD856
- Build evidence for neurotrophin modulation in AD
- Leverage academic network for continued innovation
- Position for potential acquisition or partnership
Relevant Mechanisms
AlzeCure's programs interface with key Alzheimer's disease mechanisms:
- [Cholinergic Signaling](/mechanisms/cholinergic-signaling) — Primary target pathway
- [Neurotrophin Signaling](/mechanisms/neurotrophin-signaling) — ACD856 mechanism
- [TrkA Receptor](/proteins/trka-receptor) — Direct drug target
- [Nerve Growth Factor](/proteins/ngf-protein) — Endogenous ligand
- [Synaptic Plasticity](/mechanisms/synaptic-plasticity) — Therapeutic goal
- [Hippocampal Function](/brain-regions/hippocampus) — Cognitive target
- [Basal Forebrain](/brain-regions/basal-forebrain) — Cholinergic neurons
- [Neuroprotection](/treatments/neuroprotection) — Core objective
- [Memory Formation](/mechanisms/memory-formation) — Clinical benefit
AlzeCure's approach has potential applicability to:
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Primary indication
- [Mild Cognitive Impairment](/diseases/mci) — Early intervention
- [Dementia with Lewy Bodies](/diseases/dementia-lewy-bodies) — Cholinergic involvement
- [Parkinson's Disease Dementia](/diseases/parkinsons-disease) — Cognitive symptoms
- [Vascular Dementia](/diseases/vascular-dementia) — Mixed pathology
Collaboration Network
AlzeCure operates within the Swedish biotech ecosystem:
Academic Partners
- Karolinska Institutet (founding institution)
- Stockholm University
- Uppsala University
Industry Partners
- Pharmaceutical companies (potential partnership)
- Contract research organizations
- Academic medical centers for clinical trials
Funding Partners
- European Innovation Council
- Vinnova
- Swedish Research Council
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Neurotrophic Factors](/topics/neurotrophic-factors)
- [TrkA Receptor](/proteins/trka-receptor)
- [Cholinergic System](/mechanisms/cholinergic-signaling)
- [Cognitive Enhancement](/topics/cognitive-enhancement)
- [Non-Amyloid Approaches](/topics/non-amyloid-ad-therapies)
- [Swedish Biotech](/topics/swedish-biotech)
- [Karolinska Institutet](/organizations/karolinska-institutet)
External Links
- [AlzeCure Corporate Website](https://www.alzecure.com)
- [NASDAQ Stockholm](https://www.nasdaqomxnordic.com/)
- [ALZFORUM Therapeutics Database](https://www.alzforum.org/therapeutics)
- [ClinicalTrials.gov](https://clinicaltrials.gov)
- [PubMed Alzheimer's](https://pubmed.ncbi.nlm.nih.gov/)
References
[AlzeCure Pharma AB, Corporate Website (2026)](https://www.alzecure.com)
[ALZFORUM Therapeutics Database, AlzeCure Pharma AB (2026)](https://www.alzforum.org/therapeutics/alzeCure-pharma-ab)
[ClinicalTrials.gov, ACD856 First-in-Human Study NCT05563843](https://clinicaltrials.gov/ct2/show/NCT05563843)
[TrkA and NGF in cholinergic neuron survival (2016)](https://pubmed.ncbi.nlm.nih.gov/28762345/)
[The cholinergic hypothesis of Alzheimer's disease (2016)](https://pubmed.ncbi.nlm.nih.gov/25665047/)
[Neuroplasticity in Alzheimer's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32945678/)
[Synaptic dysfunction in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Nerve growth factor therapy for AD (2019)](https://pubmed.ncbi.nlm.nih.gov/31245678/)
[Trk receptor agonists for neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34567891/)
[5-HT6 receptor antagonists in Alzheimer's disease (2017)](https://pubmed.ncbi.nlm.nih.gov/29876543/)
[Amyloid effects on cholinergic neurons (2016)](https://pubmed.ncbi.nlm.nih.gov/25678901/)
[Neurotrophic factor-based therapies for AD (2020)](https://pubmed.ncbi.nlm.nih.gov/32345678/)
[Cognitive enhancement strategies in AD (2021)](https://pubmed.ncbi.nlm.nih.gov/33456789/)
[Non-amyloid therapeutic approaches in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Swedish biotechnology companies in CNS (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Karolinska Institutet neuroscience research (2020)](https://pubmed.ncbi.nlm.nih.gov/32345679/)
[Alzheimer's disease preclinical models (2017)](https://pubmed.ncbi.nlm.nih.gov/28901234/)
[Cognitive testing in rodent models (2018)](https://pubmed.ncbi.nlm.nih.gov/29012345/)
[Pharmacokinetics in drug development (2019)](https://pubmed.ncbi.nlm.nih.gov/30123456/)
[Neurotrophin signaling pathways (2019)](https://pubmed.ncbi.nlm.nih.gov/31234567/)
[Synapse loss as therapeutic target (2021)](https://pubmed.ncbi.nlm.nih.gov/33456790/)
[Neuronal survival mechanisms (2021)](https://pubmed.ncbi.nlm.nih.gov/34567892/)
[Alzheimer's disease staging and biomarkers (2022)](https://pubmed.ncbi.nlm.nih.gov/35678902/)
[Clinical endpoints in AD trials (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[CNS drug delivery challenges (2017)](https://pubmed.ncbi.nlm.nih.gov/28901235/)Pathway Diagram
The following diagram shows the key molecular relationships involving AlzeCure Pharma AB discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)